Review of Toxoplasmosis: What We Still Need to Do
- PMID: 40872723
- PMCID: PMC12390377
- DOI: 10.3390/vetsci12080772
Review of Toxoplasmosis: What We Still Need to Do
Abstract
Toxoplasma gondii is responsible for the disease toxoplasmosis and has the broadest host range among apicomplexan parasites, as it infects virtually all warm-blooded vertebrates. Toxoplasmosis is a zoonotic and emerging public health concern with considerable morbidity and mortality, especially in the developing world, affecting approximately one-third of the world's human population. Clinical presentation varies among species, and the infection establishes lifelong chronicity in hosts. Most of the host species (including healthy humans) are asymptomatic on the one hand, it is fatal to marsupials, neotropical primates and some marine mammals on the other hand. In immunocompetent humans, infection is typically asymptomatic, whereas immunocompromised individuals may develop disseminated disease affecting virtually any organ system-most commonly reproductive, cerebral, and ocular systems. Toxoplasmosis spreads by ingestion of food or water contaminated with T. gondii oocysts, consumption of undercooked/raw meat containing tissue cysts, transplacental transmission from mother to fetus, or by receiving infected organ/blood from the infected individual. Toxoplasmosis is mainly diagnosed by serologic tests and polymerase chain reaction (PCR). It is treated with pyrimethamine combined with sulfadiazine or clindamycin, often supplemented with leucovorin, atovaquone, and dexamethasone. Despite having many potent anti-T. gondii antigenic candidates, there is no commercially available vaccine for humans due to many factors, including the complex life cycle of the parasite and its evasion strategies. To date, the only commercially available anti-T. gondii vaccine is for sheep, licensed for veterinary use to prevent ovine abortions. In this review, we have summarized the current understanding of toxoplasmosis.
Keywords: Toxoplasma gondii; control; diagnosis; lifecycle; treatment.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures




Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
[Retrospective evaluation of serologic and molecular test results of toxoplasmosis suspected patients].Mikrobiyol Bul. 2019 Jan;53(1):96-105. doi: 10.5578/mb.67469. Mikrobiyol Bul. 2019. PMID: 30683043 Turkish.
-
Ophthalmia Neonatorum.2025 Jul 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31855399 Free Books & Documents.
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
-
Primaquine for reducing Plasmodium falciparum transmission.Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008152. doi: 10.1002/14651858.CD008152.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2014 Jun 30;(6):CD008152. doi: 10.1002/14651858.CD008152.pub3. PMID: 22972117 Updated.
References
-
- Splendore A. Un Nuovo Protozoa Parassita Deconigli Incontrato Nelle Lesioni Anatomiche d’une Malattia Che Ricorda in Molti Punti Il Kala-Azar Dell’uoma. Nota Preliminare Pel. Rev. Soc. Sci. Sao Paulo. 1908;3:109–112.
-
- Weiss L., Kim K. Toxoplasma gondii: The Model Apicomplexan. Perspectives and Methods. 3rd ed. Elsevier; London, UK: 2020.
-
- Dubey J.P. Toxoplasmosis of Animals and Humans. 3rd ed. CRC Press; Boca Raton, FL, USA: Taylor & Francis Group; Abingdon, UK: 2022.
Publication types
LinkOut - more resources
Full Text Sources